2525 Background: SC is a humanized anti-HGF IgG1 MAb with potent antitumor effects in vitro and in xenograft models. The HGF/c-Met pathway mediates cell proliferation, angiogenesis, survival, migration, and invasion. Preclinical studies indicate potent additivity when combined with EGFR inhibitors. Methods: A phase I study (3+3 design) evaluated the safety, tolerability, recommended phase II dose (RP2D), pharmacokinetics (PK), and pharmacodynamics (PD) of SC. Monotherapy SC was given IV over 30-60 min, at 2, 5, 10, or 20 mg/kg once every 2 weeks. At the RP2D of SC, E at a dose of 150 mg/d was evaluated. At RP2D, cohorts were expanded to a total of 12 pts. Results: 37 pts (15M/22F, median age 63, range 18-87, ECOG PS 0/1/2: 10/26/1) have been enrolled. 24 pts with monotherapy SC were treated at 2 (n=3), 5 (n=3), 10 (n=3), or 20 mg/kg (n=15). 13 pts received the combination of SC 20mg/kg and E 150 mg/d. Most common tumors were sarcoma (6), ovarian (4), mesothelioma (3), and GBM (3). There were no dose-limit...